Opinion|Videos|September 4, 2024
Navigating Insurance Challenges and Transitions of Care in Hepatic Encephalopathy (HE)
The panel navigates insurance coverage during patient discharge for HE and the significance of ensuring medication access post-discharge.
Advertisement
Episodes in this series
This series was supported by Salix Pharmaceuticals.
Advertisement
Related to this article
As peptides go mainstream, the FDA's shifting rules and a fractured state patchwork leave patients navigating a largely unregulated gray market.
Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.
A large propensity-matched study linked outpatient melatonin use to a small reduction in REM sleep in children evaluated for polysomnography.
Prior authorization and compounded drugs remain top obesity care access barriers, says NYU Langone's Holly Lofton, MD.
Panelists say IRA, Most Favored Nation rules and fragmented data are freezing value-based deals for durable one-time therapies.
Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.
FDA approved belzutifan plus lenvatinib for advanced ccRCC after PD-1/PD-L1 therapy, expanding treatment options for those with disease progression.
A 3-year registry found dupilumab controlled atopic dermatitis (AD) in most children, though those under 6 years were likelier to stop treatment.
Advertisement
Advertisement
Trending on AJMC
1
Surrogate End Points, Drug Costs Complicate Oncology Formularies
2
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
3
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
4
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
5